ERBB2 and breast carcinoma: The present study suggested that the genetic liability to critically ill COVID-19 increased the risk of HER2-positive breast cancer possibly via immune cells, providing a new pathway for researchers to investigate the biological mechanisms of HER2-positive breast cancer, potentially leading to new therapeutic targets.